Vor Biopharma Inc. (VOR) Form 10-Q — Oct 30, 2026
Vor Biopharma reported a Q3 2026 net loss of $86.7 million and nine-month net loss of $369.1 million, with $481.6 million in cash, cash equivalents and marketable securities expected to fund operations into early 2029. The company completed enrollment in its UPSTREAM MG Phase 3 trial of telitacicept in generalized myasthenia gravis, with topline data anticipated in the first half of 2027, and plans to initiate a registrational Phase 3 in ocular myasthenia gravis with enrollment beginning in 1H 2027.
Key figures
- Total Assets
- 496312000
- Cash Position
- 78977000
- Shares Outstanding
- 61434344
- Runway
- into early 2029
- Q3 2026 g and a
- $23.9 million
- Q3 2026 r and d
- $34.5 million
- Atm capacity new
- $150.0 million (William Blair / RBC, Oct 30, 2026)
- Q3 2026 net loss
- $86.7 million
- Accumulated deficit
- $1,522.1 million
- Warrant liabilities
- $594.7 million
- Nine month 2026 net loss
- $369.1 million
- Outstanding 2025 warrants
- 31172260
- Cash cash equivalents marketable securities
- $481.6 million
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.